The same dataset was analyzed according to the high-risk Neuroblastoma Study 1.7 of SIOPEurope (SIOPEN) stratification risk, where HR-NB is defined as stages 2, 3, 4, and 4S with MYCN-amplification and stage 4 MYCN non-amplified > 12 months at diagnosis. This evidence concerns the gene MYCN and neuroblastoma.